Iluvien (Fluocinolone Acetonide)

Fluocinolone acetonide binds to glucocorticoid receptors in ocular tissues, modulating gene transcription. This reduces production of inflammatory cytokines, decreases vascular permeability, and limits leukocyte infiltration, thereby lowering retinal fluid accumulation and preventing further damage in diabetic macular edema.

The dose of Iluvien is determined by the prescribing ophthalmologist. The implant contains a fixed 0.19 mg of fluocinolone acetonide and is inserted as a single intravitreal device; the clinician decides whether it is appropriate based on the patient’s disease status and prior treatments.

The safety of Iluvien in pregnancy or lactation has not been established, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies the potential risk, and clinicians should discuss uncertainties with the patient.

To request Iluvien, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with repeated intravitreal anti‑VEGF injections, Iluvien offers a sustained‑release corticosteroid platform that can last up to three years, reducing injection frequency. However, it carries a higher risk of intraocular pressure elevation and cataract formation, so patient selection and monitoring differ from anti‑VEGF therapies.

Iluvien must be stored at 2–8 °C in its original packaging, protected from light, and must not be frozen or shaken. Prior to implantation, the device should be allowed to reach room temperature if required by the surgical protocol, and handled only by trained personnel in a sterile environment.

Iluvien is implanted by an ophthalmic surgeon using a specialized intravitreal delivery system. The implant is placed through the pars plana into the vitreous cavity, where it slowly releases fluocinolone acetonide over several years. The procedure is performed under aseptic conditions, typically in an operating‑room setting.

The most serious adverse events include sustained elevation of intraocular pressure that may require surgical intervention, development of cataract necessitating extraction, and rare but vision‑threatening complications such as endophthalmitis, retinal detachment, or implant migration. Prompt monitoring and early management are essential to mitigate these risks.

Iluvien is contraindicated in eyes with active ocular infection, uncontrolled glaucoma, or known hypersensitivity to fluocinolone acetonide or any component of the implant. Patients with a history of steroid‑induced intraocular pressure spikes or those unable to attend regular follow‑up should be evaluated carefully before implantation.